Drug Profile
Research programme: infectious disease therapeutics - Sanofi/Oswaldo Cruz Foundation
Alternative Names: Anti-TGFβ monoclonal antibodies - Sanofi/Oswaldo Cruz Foundation; Anti-transforming growth factor beta monoclonal antibodies - Sanofi/Oswaldo Cruz Foundation; Chagas disease therapeutics - Sanofi/Oswaldo Cruz FoundationLatest Information Update: 01 Apr 2022
Price :
$50
*
At a glance
- Originator Genzyme Corporation; Oswaldo Cruz Foundation
- Developer Oswaldo Cruz Foundation; Sanofi
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Trypanosomiasis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Trypanosomiasis in Latin America
- 08 Apr 2011 Genzyme Corporation has been acquired by sanofi-aventis
- 21 Sep 2010 This programme is still active